초등학교 근시 환아에서 저농도 아트로핀 점안이 근시 진행에 미치는 영향
Efficacy of Low-dose Atropine Eyedrops in Myopic Progression in Elementary School Children
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
목적: 초등학교 근시 환아에서 저농도 아트로핀 점안이 근시 진행에 미치는 효과를 연구하였다. 대상과 방법: 저농도 아트로핀 점안 전, 후 6개월간 의무기록을 후향적으로 분석하였다. 점안 방법은 저농도 아트로핀(atropine sulfate 0.125%) 점안 후 인공누액(sodium hyaluronate 0.1%)을 양안에 점안하는 방법으로 매일 1회 점안하였다. 대조군은 근시 환아들을대상으로 하였다. 굴절이상, 안축장길이, 동공 크기, 조절근점을 측정하였으며 6개월 동안 두통, 눈부심 등 증상을 조사하였다. 결과: 116명의 환자 중 아트로핀 점안군은 65명, 대조군은 51명이었다. 아트로핀 점안군의 연령은 10.2 ± 1.8세 (6-11세)였다. 처음방문 시 굴절이상은 -4.7 ± 2.1 D (-1.0 to -10.5), 안축장길이는 24.95 ± 1.02 mm (22.58-27.99)였고 6개월 후 굴절이상의 변화는-0.9 ± 1.1 D (-0.75 to -4.75), 안축장길이 변화는 0.47 ± 0.39 mm (0.01-1.6)였다. 저농도 아트로핀 점안 6개월 후 굴절력의 변화는-0.1 ± 0.2 D (0 to -0.25)였고 안축장길이 변화는 0.15 ± 0.23 mm (0-1.05)로 유의하게 감소하였다(p＜0.001). 동공 크기는 6.7 ± 0.6 mm (5.3-9.3)였고 조절근점은 6.1 ± 2.0 cm (3.1-11.0)였다. 근거리 작업 불편은 2명(3.1%)에서 관찰되었다. 결론: 저농도 아트로핀 점안은 초등학교 환아에서 근시 억제에 효과가 있을 것으로 생각된다.
Abstract
Purpose: We analyzed the effects of low-dose atropine on myopic progression in elementary schoolchildren aged 6-11 years. Methods: Medical records were retrospectively reviewed before and after 6 months of low-dose atropine eyedrops. Myopia was defined as a spherical equivalent < -1 diopter. Low-dose atropine eyedrops (atropine sulfate 0.125% [w/v]) and artificial tear eyedrops (sodium hyaluronate 0.1% [w/v]) immediately afterwards were applied to both eyes daily, and all children regularly visited us for measurement of refractive power, axial length, pupil diameter, and near-point accommodation. symptoms (headache, light sensitivity, near-work disturbance, allergic reaction, dry eye, and poor night vision) were recorded. Results: A total of 116 patients were included. Atropine was prescribed for 65 patients, the remaining 51 patients constituted the control group. In the atropine group, the mean age was 10.2 ± 1.8 years and 23 patients (35.4%) were male. At the initial visit, the mean refractive power was -4.7 ± 2.1 diopters (D) (-1.0 to -10.5) and the mean axial length was 24.95 ± 1.02 mm (22.58-27.99). At the 6-month follow-up, the change of refractive power was -0.9 ± 1.1 D (-0.75 to -4.75) and the change of axial length was 0.47 ± 0.39 mm (0.01-1.6). However, 6 months after application of low-dose atropine eyedrops, the change of refractive power was -0.1 ± 0.2 D (0 to -0.25) and the change of mean axial length was 0.15 ± 0.23 mm (0-1.05). The mean pupil diameter was 6.7 ± 0.6 mm (5.3-9.3) and the near accommodation point was 6.1 ± 2.0 cm (3.1-11.0). Two patients (3.1%) complained of near-work disturbance but none stopped taking the eyedrops. Conclusions: Significant decreases in the changes of refractive power and axial length were evident in myopic elementary schoolchildren after low-dose atropine therapy. Low-dose atropine attenuates myopic progression without severe complications.
참고문헌 (14)
- Holden BA, "Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050", Ophthalmology, 123, pp.1036~1042 (2016)
- 정승일, "국민건강영양조사(2008-2012) 자료를 이용한 소아의 근시 진행 경향에 대한 분석", 대한안과학회지, 57(9), pp.1430~1434 (2016), 대한안과학회
- Tay SA, "Interventions to reduce myopia progression in children", Strabismus, 25, pp.23~32 (2017)
- 최태호, "아트로핀이 소아 근시진행에 미치는 영향", 대한안과학회지, 46(7), pp.1189~1195 (2005), 대한안과학회
- Wang IJ, "The effect of intravitreal injection of atropine on the proliferation of scleral chondrocyte in vivo", J Ocul Pharmacol Ther, 14, pp.337~343 (1998)
- Chua WH, "Atropine for the treatment of childhood myopia", Ophthalmology, 113, pp.2285~2291 (2006)
- Chia A, "Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops", Ophthalmology, 123, pp.391~399 (2016)
- Li FF, "Low-concentration atropine eye drops for myopia progression", Asia Pac J Ophthalmol(Phila), 8, pp.360~365 (2019)
- Yam JC, "Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control", Ophthalmology, 126, pp.113~124 (2019)
- Zhu Q, "Efficacy and safety of 1% atropine on retardation of moderate myopia progression in Chinese school children", Int J Med Sci, 17, pp.176~181 (2020)
- Khanal S, "Which low-dose atropine for myopia control?", Clin Exp Optom, 103, pp.230~232 (2020)
- Wu PC, "Update in myopia and treatment strategy of atropine use in myopia control", Eye(Lond), 33, pp.3~13 (2019)
- Lara F, "Changes in the objective amplitude of accommodation with pupil size", Optom Vis Sci, 91, pp.1215~1220 (2014)
- Schaeffel F, "Animal models in myopia research", Clin Exp Optom, 98, pp.507~517 (2015)